1. Friend or Foe: S100 Proteins in Cancer
- Author
-
Johannes Lemke, Chantal Allgöwer, Mathias Wittau, Doris Henne-Bruns, Silvia von Karstedt, and Anna-Laura Kretz
- Subjects
0301 basic medicine ,Cancer Research ,Inflammation ,Review ,Biology ,Bioinformatics ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,medicine ,Ca2+-dependent signalling ,Lung cancer ,integumentary system ,Melanoma ,biomarkers ,Cancer ,Diagnostic marker ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Review article ,Cancer treatment ,stomatognathic diseases ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,cancer therapy ,medicine.symptom ,S100 proteins - Abstract
S100 proteins are widely expressed small molecular EF-hand calcium-binding proteins of vertebrates, which are involved in numerous cellular processes, such as Ca2+ homeostasis, proliferation, apoptosis, differentiation, and inflammation. Although the complex network of S100 signalling is by far not fully deciphered, several S100 family members could be linked to a variety of diseases, such as inflammatory disorders, neurological diseases, and also cancer. The research of the past decades revealed that S100 proteins play a crucial role in the development and progression of many cancer types, such as breast cancer, lung cancer, and melanoma. Hence, S100 family members have also been shown to be promising diagnostic markers and possible novel targets for therapy. However, the current knowledge of S100 proteins is limited and more attention to this unique group of proteins is needed. Therefore, this review article summarises S100 proteins and their relation in different cancer types, while also providing an overview of novel therapeutic strategies for targeting S100 proteins for cancer treatment.
- Published
- 2020
- Full Text
- View/download PDF